Abstract
Pulmonary fibrosis is becoming a recognized complication of coronavirus disease 2019 (COVID-19). We report 2 cases of 2 patients aged 40 and 61 with pulmonary fibrosis due to COVID-19. The clinical examination showed that the 2 patients were dyspneic with a weak oxygen saturation and that there was bilateral crackles of the two pulmonary fields. High-resolution computed tomography showed bilateral multifocal ground glass opacities, subpleural fibrotic bands (between 25-50% and 75% parenchymal involvement). We prescribed them an anti-fibrosant, nintedanib, and there was a significant clinical and radiological improvement after 15 days of treatment. Nintedanib may have a new therapeutic role in the prevention of fibrosis associated with COVID-19.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.